Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phaos Technology Holdings CaymanPOAS -6.08%4 3-Year EBITDA Growth Rate is 0.00% as of Oct. 2025. GuruFocus rates POAS with a GF Score™ of 4/100. The stock has 5 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Phaos Technology Holdings Cayman ranks worse than 144508.53% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Phaos Technology Holdings Cayman 3-Year EBITDA Growth Rate Related Terms
POAS vs WOK, ITOC, INBS: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Phaos Technology Holdings Cayman's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phaos Technology Holdings Cayman 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Phaos Technology Holdings Cayman's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Phaos Technology Holdings Cayman's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Phaos Technology Holdings Cayman (POAS) has a 3-Year EBITDA Growth Rate of 0.00% as of Oct. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Phaos Technology Holdings Cayman and its competitors. According to the industry distribution chart, Phaos Technology Holdings Cayman ranks #999999 out of 692 companies in the Medical Devices & Instruments industry.
Is Phaos Technology Holdings Cayman's 3-Year EBITDA Growth Rate too high?
Phaos Technology Holdings Cayman's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Phaos Technology Holdings Cayman ranks #999999 out of 692 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Phaos Technology Holdings Cayman has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Phaos Technology Holdings Cayman's 3-Year EBITDA Growth Rate compare to WOK and ITOC?
According to the Medical Devices & Instruments industry distribution chart, Phaos Technology Holdings Cayman ranks #999999 out of 692 companies for 3-Year EBITDA Growth Rate. This places Phaos Technology Holdings Cayman in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Phaos Technology Holdings Cayman and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phaos Technology Holdings Cayman's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phaos Technology Holdings Cayman stock overvalued right now?
Phaos Technology Holdings Cayman (POAS) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Phaos Technology Holdings Cayman's overall GF Score™ is 4/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Phaos Technology Holdings Cayman (POAS), the current 3-Year EBITDA Growth Rate is 0.00% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phaos Technology Holdings Cayman Business Description
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.
4GF Score
Get the complete analysis for POAS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POAS has been successfully added to your 
